TYTakeshi Yamasaki

Takeshi Yamasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Takeshi Yamasaki has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Junji Uchida

    Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

    4 shared publications
  • Minoru Kato

    Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

    4 shared publications
  • Taiyo Otoshi

    Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

    4 shared publications
  • Yuji Takeyama

    Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

    4 shared publications
  • Junji Uchida

    Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

    3 shared publications
  • Katsuyuki Kuratsukuri

    Department of Urology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

    3 shared publications

Latest Publications

  • Open Access

    Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study

    by Junji Uchida, Shunji Nishide, Yuji Takeyama, Taiyo Otoshi, Minoru Kato, Takeshi Yamasaki, Tomoaki Iwai, Toshihide Naganuma, Katsuyuki Kuratsukuri

    Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV outcomes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and everolimus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of baseline. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated rejection, or antibody-mediated rejection occurred during letermovir prophylaxis; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.


  • Open Access

    Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single‐Center Retrospective Study

    by Junji Uchida, Shunji Nishide, Yuji Takeyama, Taiyo Otoshi, Minoru Kato, Takeshi Yamasaki, Tomoaki Iwai, Toshihide Naganuma, Katsuyuki Kuratsukuri

    Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients. Methods: This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV out-comes, and safety were assessed descriptively. Results: After letermovir initiation, mean tacrolimus trough concentrations increased by approximately 40–60% and evero-limus trough concentrations by approximately 35–50%, requiring dose reductions of approximately 45% and 30–40%, respectively. By day 7 after discontinuation, mean tacrolimus and everolimus trough concentrations decreased to 57.4% and 65.9% of baseline, respectively, while daily doses increased to 136.6% and 132.5%, respectively. Group mean serum creatinine and eGFR remained within approximately 10% of base-line. No CMV DNAemia or disease, leukopenia, neutropenia, acute T cell-mediated re-jection, or antibody-mediated rejection occurred; gastrointestinal symptoms occurred in three recipients. Conclusions: Letermovir was associated with rapid, reversible changes in tacrolimus and everolimus trough concentrations and dose requirements. Intensive therapeutic drug monitoring is warranted at both initiation and discontinuation.


  • Recurrence Risk Stratification in Clear Cell Renal Cell Carcinoma Using TNM 2017 and WHO/ISUP Grade

    by Kosuke Hamada, Takeshi Yamasaki, Chisato Ohe, Nozomi Tsujio, Shoma Yamamoto, Taisuke Matsue, Nao Yukimatsu, Taiyo Otoshi, Minoru Kato, Katsuyuki Kuratsukuri, et al.

    To re-evaluate established recurrence risk models for clear cell renal cell carcinoma (ccRCC) using the tumor, node, metastasis (TNM) 2017 classification and the World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading system, and to perform an exploratory analysis of whether these updates improve the predictive accuracy of recurrence risk models. We retrospectively analyzed 295 patients who underwent surgery for non-metastatic ccRCC at Osaka Metropolitan University Hospital between 2013 and 2020. Pathological features were re-evaluated using both the TNM 2009 and TNM 2017 classifications, as well as the Fuhrman and WHO/ISUP grading systems. We examined the frequency of pathological upstaging to pT3a and compared recurrence predictions across grading systems. In addition, we assessed recurrence risk stratification using the Leibovich 2003 and 2018 models with updated pathological classifications. Recurrence-free survival (RFS) was assessed using Kaplan-Meier analysis, and prognostic accuracy was evaluated using Harrell's concordance index (C-index). Among cT1 cases, pathological upstaging to pT3a occurred more frequently according to TNM 2017 (18.9%) than TNM 2009 (16.0%). TNM 2017 showed superior prognostic performance for predicting recurrence in cT1 tumors (C-index, 0.748 vs. 0.726). The WHO/ISUP grade demonstrated greater predictive accuracy than the Fuhrman grade (C-index, 0.817 vs. 0.737). The C-index of the Leibovich 2003 model improved from 0.812 (TNM 2009 plus Fuhrman classification) to 0.834 (TNM 2017 plus the WHO/ISUP classification). The highest predictive accuracy was achieved using the Leibovich 2018 model (C-index, 0.870). Re-evaluation using TNM 2017 and WHO/ISUP grading was associated with improved predictive accuracy of recurrence risk models for localized ccRCC and may aid postoperative risk stratification.

  • Open Access

    Robot-assisted laparoscopic radical nephrectomy for renal cell carcinoma with direct colon invasion and concomitant inferior vena cava tumor thrombus: A case report

    by Kosuke Hamada, Takeshi Yamasaki, Nawa Masaki, Shoma Yamamoto, Taisuke Matsue, Nao Yukimatsu, Taiyo Otoshi, Minoru Kato, Katsuyuki Kuratsukuri, Junji Uchida

  • Open Access

    Surgical Outcomes of the Non‐renorrhaphy Technique During Robot‐Assisted Partial Nephrectomy for Highly Complex Renal Tumors ( RENAL Score ≥ 10)

    by Kosuke Hamada, Takeshi Yamasaki, Shoma Yamamoto, Taisuke Matsue, Nao Yukimatsu, Taiyo Otoshi, Minoru Kato, Katsuyuki Kuratsukuri, Junji Uchida

    Objectives: Non‐renorrhaphy technique during partial nephrectomy has not been sufficiently studied. This study aimed to evaluate the surgical outcomes of the non‐renorrhaphy technique in robot‐assisted partial nephrectomy (RAPN) for tumors with RENAL scores of 10–12. Methods: We retrospectively analyzed 51 consecutive patients who underwent RAPN with or without renorrhaphy for RENAL score 10–12 tumors at Osaka Metropolitan University Hospital between March 2015 and December 2023. Perioperative outcomes were compared between 16 patients in the nonrenorrhaphy group and 35 patients in the renorrhaphy group. Univariate and multivariate linear regression analyses were conducted to identify predictors of renal function and renal parenchymal volume preservation. Results: Patient demographics and preoperative tumor characteristics exhibited no significant differences between the two groups. Operative time was significantly shorter in the nonrenorrhaphy group (185 vs. 217 min, p = 0.0016). The preservation rate of renal parenchymal volume was significantly higher in the nonrenorrhaphy group (86.7 vs. 74.2%, p = 0.0016), but there was no significant difference in the preservation rate of estimated glomerular filtration rate ( p = 0.6380). No significant difference was observed in the incidence of major complications (Clavien‐Dindo grade ≥ 3) between the two groups. Urinary leakage occurred in both groups ( p = 0.9399). In univariate and multivariate analyses, renorrhaphy and clinical tumor size were identified as significant predictors of renal parenchymal volume preservation. Conclusions: Even in cases with RENAL scores of 10–12, the non‐renorrhaphy technique appears to be a feasible and safe approach, and may be associated with better preservation of renal parenchymal volume.


  • Open Access

    Case in which percutaneous fibrin glue injection was useful for refractory urinary fistula following robot‐assisted partial nephrectomy

    by Nao Yukimatsu, Takeshi Yamasaki, Keiko Iguchi, Taiyo Otoshi, Minoru Kato, Junji Uchida

    Introduction: Urinary fistula is a rare complication following robot‐assisted partial nephrectomy. For cases refractory to conservative treatment, only ureteral stent placement and percutaneous drainage are the established treatment alternatives.Case presentation: A 44‐year‐old man presented with urinary fistula 3 weeks after robot‐assisted partial nephrectomy for right renal cell carcinoma. Follow‐up observations were conducted for 2 weeks; however, no improvements were observed. Additionally, the patient did not improve following percutaneous drainage and ureteral stent insertion. Subsequently, the patient received percutaneous injections of fibrin glue, with the urinary fistula showing significant improvements on the following day.Conclusion: Our findings indicated that percutaneous fibrin glue injection can effectively treat refractory urinary fistula following partial nephrectomy.


  • Open Access

    Trend in overall survival from the start of first-line chemotherapy in patients with metastatic urothelial carcinoma

    by Shoma Yamamoto, Minoru Kato, Taisuke Matsue, Nao Yukimatsu, Yuji Takeyama, Taiyo Otoshi, Takeshi Yamasaki, Katsuyuki Kuratsukuri, Junji Uchida

    New approaches involving immune checkpoint inhibitors and antibody-drug conjugates prolong overall survival in patients with metastatic urothelial carcinoma. However, the access to such systemic therapy in clinical practice is suboptimal, and whether these agents improve overall survival in patients with metastatic urothelial carcinoma over time remains unclear. Hence, we investigated the overall survival trend from the initiation of first-line therapy with these agents to identify changes due to the medication and time of treatment initiation. We retrospectively evaluated 195 patients from a single center. They were treated with chemotherapy, pembrolizumab, or avelumab or enfortumab vedotin. The treatment was categorized into chemotherapy, pembrolizumab or avelumab/enfortumab vedotin period. The new agents prolonged overall survival from the start of first-line therapy. Furthermore, sequential treatment with these agents in real-world clinical practice has been reported to prolong overall survival. These study results will have major implications when a new first-line therapy is approved in the future.

  • Open Access

    Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer

    by Yuji Takeyama, Minoru Kato, Satoshi Tamada, Yukari Azuma, Yasuomi Shimizu, Taro Iguchi, Takeshi Yamasaki, Min Gi, Hideki Wanibuchi, Tatsuya Nakatani


  • Open Access

    Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

    by Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Takeshi Yamasaki, Tatsuya Nakatani

    Enzalutamide is an oral androgen receptor targeted agent that has been shown to improve survival in PREVAIL trials and has been approved for patients with chemo-naïve metastatic castration-resistant prostate cancer (CRPC). Meanwhile, flutamide is a non-steroidal oral anti-androgen that was commonly used before the approval of bicalutamide. The objective of the OCUU-CRPC study is to compare the efficacy and safety between second-line hormonal therapy of enzalutamide and flutamide as alternative anti-androgen therapy (AAT) after combined androgen blockade (CAB) therapy that included bicalutamide in patients with CRPC. A total of 100 patients with CRPC with or without distant metastases after disease progression who received CAB therapy with bicalutamide were randomly assigned at a 1:1 ratio according to distant metastases to the enzalutamide (160 mg/day, 4 × 40 mg capsules once daily) and flutamide (375 mg/day; 3 × 125 mg tablets thrice daily) groups. The primary endpoint for the drug efficacy is the response rate of prostate-specific antigen (PSA) (i.e., the ratio of patients whose PSA declined by ≥50% from baseline) at 3 months. Meanwhile, the secondary endpoints are PSA progression rate at 3 and 6 months, PSA response rate at 6 months, change in quality of life, PSA progression-free survival, and safety. The patient registration started in January 2015 and will end in March 2018, and the follow-up period is 6 months after the last patient registration. The main result will be reported in March 2019. In the OCUU-CRPC study, we compare the efficacy and safety of enzalutamide or alternative AAT with flutamide in participants with CRPC who were previously treated with a CAB therapy with bicalutamide. The expected results of this study will be that enzalutamide is superior to flutamide in terms of PSA response. A longer time to disease progression with enzalutamide over flutamide may translate to better overall survival. However, flutamide may be more accessible for patients owing to its lower cost than enzalutamide. The OCUU-CRPC study was prospectively registered at clinicaltrials.gov ( NCT02346578 , January 2015) and University Hospital Medical Information Network ( UMIN000016301 , January 2015).


  • Open Access

    A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

    by Jumpei Asakawa, Taro Iguchi, Satoshi Tamada, Sayaka Yasuda, Noriko Ninomiya, Minoru Kato, Takeshi Yamasaki, Tetusji Ohmachi, Tatsuya Nakatani

    The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of changing the treatment from degarelix to a gonadotropin releasing hormone agonist after achieving stable disease control, on the clinical and oncological outcomes. Our analysis was based on the data of 108 patients with prostate cancer who were treated with degarelix. Of these, the treatment was changed from degarelix to a gonadotropin releasing hormone agonist in 57 patients (changed group), and the treatment with degarelix was continued in the other 51 (continued group). The overall 5-year survival was statistically superior in the changed (96.6%) group than that in the continued (74.1%) group (p = 0.006). The 5-year cancer-specific survival was also superior in the changed (100%) group than that in the continued (84.6%) group (p = 0.027). The average time to castration resistant prostate cancer was comparable in both the changed (43.3 months) and continued (35.2 months) groups (p = 0.117). Lower serum levels of prostate specific antigen and alkaline phosphatase were maintained after changing the therapy from degarelix to a gonadotropin releasing hormone agonist. Degarelix is effective in the treatment of prostate cancer. Degarelix therapy can also be safely changed to a gonadotropin releasing hormone agonist without any adverse clinical or oncological effects.